On or around 09/01/2017 (Ongoing date of last review)
Filing Date: January 27, 2017
According to the law firm press release, the complaint alleges that, among other allegations, throughout the Class Period, Egalet made materially false and/or misleading statements concerning its lead product, ARYMO ER and the likelihood the product would receive oral abuse-deterrent labeling.
On May 1, 2017, the Court appointed lead plaintiffs and counsel.
Company & Securities Information
Defendant: Egalet Corporation
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: EGLT
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
George Mineff, et al. v. Egalet Corporation, et al.